AAminove
Back to library

Sermorelin

Human observationalWADA prohibited

Also known as: GHRH (1-29)

Growth-hormone secretagoguesGHRH analogueHistorically a diagnostic agent

Community-reported ranges are anecdotal and not clinically validated. Evidence grade shown reflects the strength of available human data. Not a prescription. Legal status varies by country and changes over time; verify locally.

Overview

A GHRH analogue previously used diagnostically for GH deficiency. Marketed today for anti-ageing with weaker support for those uses.

Mechanism

Stimulates pituitary growth-hormone secretion as a GHRH analogue.

Evidence

Human observationalWhat does this mean?

Some historical human use as a diagnostic; anti-ageing/physique claims are weakly supported.

Community-reported information

Prescription/compounded contexts vary. Anecdotal outside those; general information only.

General information only, not tailored to you and not a recommendation. Some regions withhold this entirely.

Half-life

~10–20 minutes.

Storage

Refrigerate.

Commonly reported side effects

  • Flushing
  • Injection-site reactions
  • Headache

Legal status by region

  • USHistorically available; compounding status has changed — verify current status.

Legal status changes over time; verify locally before relying on this.

Citations